Actuate Therapeutics Inc

NASDAQ: ACTU · Healthcare · Biotechnology

PublicHQ Fort Worth, TX · TarrantCIK 0001652935Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 29DQ —GM —SS 30

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ listing tenure, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$22.2M

Employees

as of 2026-08-20

Market cap

$25.4M

as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$22.2M-$22.2M2025

Operating income-$22.5M-$22.5M2025

Total assets$14.0M$14.0M2025

Liabilities$6.1M$6.1M2025

Equity$7.9M$7.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Actuate Therapeutics Inc’s financial profile?

Actuate Therapeutics Inc earned -$22.2M in FY2025 net income.

Peers · Healthcare

Sangamo Therapeutics, Inc.——HeartBeam, Inc.——Tevogen Bio Holdings Inc.——NurExone Biologic Inc.——Quantum BioPharma Ltd.——Werewolf Therapeutics, Inc.——

Neighbors

Tarrant →

The Charles Schwab Corporation$23.9B74B D.R. Horton, Inc.$34.3B79B+TPG Inc.$2.4B57C American Airlines Group Inc.$54.6B65B FirstCash Holdings, Inc$1.7B82B+Range Resources Corporation$3.0B83B+

Key facts

CEODaniel Schmitt

SectorHealthcare

IndustryBiotechnology

HeadquartersFort Worth, TX

ExchangeNASDAQ: ACTU

Employees12

IPO date2024-08-13

Latest filings

10-Q2026-08-14 8-K2026-07-17 8-K2026-05-22 10-Q2026-05-14 8-K2026-05-11 8-K2026-05-06 DEF 14A2026-04-06 10-K2026-03-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.